Can You Switch from Risperdal to Aristada for Maintenance Treatment?
Yes, switching from Risperdal (oral risperidone) to Aristada (aripiprazole lauroxil, a long-acting injectable) is possible for maintenance therapy in schizophrenia or bipolar I disorder, but it requires medical supervision to manage dosing transitions and monitor for risks like relapse or side effects.[1][2]
How Do Doctors Handle the Switch?
Initiate Aristada after stabilizing on oral aripiprazole (10-20 mg daily) for 14 consecutive days to confirm tolerability. Risperdal can often be tapered during this overlap period. Aristada dosing starts at 441 mg, 662 mg, or 882 mg intramuscularly every 4-6 weeks, depending on response.[2][3] No direct conversion from risperidone exists; clinicians adjust based on prior dose, symptoms, and factors like CYP2D6 metabolism.
What Are the Key Differences Between Risperdal and Aristada?
| Aspect | Risperdal (Risperidone) | Aristada (Aripiprazole Lauroxil) |
|--------|--------------------------|----------------------------------|
| Form | Oral tablet/liquid | Long-acting injectable (monthly or longer) |
| Mechanism | Strong D2/5-HT2A antagonist; higher prolactin elevation | Partial D2 agonist; lower prolactin risk |
| Maintenance Use | Daily dosing; adherence challenges common | Improves adherence; steady blood levels |
| Common Side Effects | Weight gain, sedation, extrapyramidal symptoms (EPS), hyperprolactinemia | Akathisia, injection site pain, weight gain (less than risperidone) |
Aristada reduces relapse risk by 69-79% vs. placebo in trials, similar to other atypicals.[2][4]
What Risks Come with Switching?
- Withdrawal or relapse: Abrupt Risperdal stop can worsen psychosis; taper gradually.
- Overlapping effects: Both raise EPS risk initially; monitor for akathisia (up to 18% with Aristada).[2]
- QT prolongation: Rare but possible; ECG if cardiac history.
- Special cases: Avoid in dementia-related psychosis (black box warning for both); caution in pregnancy or elderly.[1][3]
Patients report easier adherence with Aristada but note painful injections.[5]
When Does Insurance or Cost Play a Role?
Aristada costs $2,000-$3,000 per injection (uninsured); copay cards lower it to $0-$30 for eligible patients.[6] Medicare/Medicaid often covers after oral trial. Risperdal generics are cheaper ($10-50/month), so switching may raise out-of-pocket costs unless prior authorization approves for non-adherence.
Who Makes Aristada and Any Patent Issues?
Alkermes manufactures Aristada, approved by FDA in 2015.[2] Key patents expire around 2030-2033, delaying generics; check DrugPatentWatch.com for updates on challenges.[7]
[1] Risperdal Prescribing Information, Janssen.
[2] Aristada Prescribing Information, Alkermes. Link
[3] FDA Label for Aristada. Link
[4] Calabrese et al., Am J Psychiatry (2017).
[5] Patient reviews on Drugs.com.
[6] GoodRx pricing data.
[7] DrugPatentWatch.com. Link